363 related articles for article (PubMed ID: 28545552)
1. hrHPV E5 oncoprotein: immune evasion and related immunotherapies.
de Freitas AC; de Oliveira THA; Barros MR; Venuti A
J Exp Clin Cancer Res; 2017 May; 36(1):71. PubMed ID: 28545552
[TBL] [Abstract][Full Text] [Related]
2. HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy.
Paolini F; Curzio G; Cordeiro MN; Massa S; Mariani L; Pimpinelli F; de Freitas AC; Franconi R; Venuti A
Hum Vaccin Immunother; 2017 Feb; 13(2):291-297. PubMed ID: 27929754
[TBL] [Abstract][Full Text] [Related]
3. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer.
Sasagawa T; Takagi H; Makinoda S
J Infect Chemother; 2012 Dec; 18(6):807-15. PubMed ID: 23117294
[TBL] [Abstract][Full Text] [Related]
4. Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers.
Barros MR; de Oliveira THA; de Melo CML; Venuti A; de Freitas AC
J Immunol Res; 2018; 2018():2912671. PubMed ID: 29854832
[TBL] [Abstract][Full Text] [Related]
5. Evasion of host immune defenses by human papillomavirus.
Westrich JA; Warren CJ; Pyeon D
Virus Res; 2017 Mar; 231():21-33. PubMed ID: 27890631
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus type 16 E5 protein as a therapeutic target.
Kim SW; Yang JS
Yonsei Med J; 2006 Feb; 47(1):1-14. PubMed ID: 16502480
[TBL] [Abstract][Full Text] [Related]
7. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
[TBL] [Abstract][Full Text] [Related]
8. Suppression of Stromal Interferon Signaling by Human Papillomavirus 16.
Raikhy G; Woodby BL; Scott ML; Shin G; Myers JE; Scott RS; Bodily JM
J Virol; 2019 Oct; 93(19):. PubMed ID: 31292244
[TBL] [Abstract][Full Text] [Related]
9. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV.
Miura S; Kawana K; Schust DJ; Fujii T; Yokoyama T; Iwasawa Y; Nagamatsu T; Adachi K; Tomio A; Tomio K; Kojima S; Yasugi T; Kozuma S; Taketani Y
J Virol; 2010 Nov; 84(22):11614-23. PubMed ID: 20810727
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment.
Kim MK; Kim HS; Kim SH; Oh JM; Han JY; Lim JM; Juhnn YS; Song YS
Biochem Pharmacol; 2010 Dec; 80(12):1930-5. PubMed ID: 20643111
[TBL] [Abstract][Full Text] [Related]
11. Immune evasion mechanisms of human papillomavirus: An update.
Steinbach A; Riemer AB
Int J Cancer; 2018 Jan; 142(2):224-229. PubMed ID: 28865151
[TBL] [Abstract][Full Text] [Related]
12. Animal models of papillomavirus pathogenesis.
Campo MS
Virus Res; 2002 Nov; 89(2):249-61. PubMed ID: 12445664
[TBL] [Abstract][Full Text] [Related]
13. Association of human papillomavirus infection and inflammation in cervical cancer.
Hemmat N; Bannazadeh Baghi H
Pathog Dis; 2019 Jul; 77(5):. PubMed ID: 31504464
[TBL] [Abstract][Full Text] [Related]
14. Is there a role played by HLA-E, if any, in HPV immune evasion?
Franciosi JR; Gelmini GF; Roxo VS; de Carvalho NS; Bicalho MDG
Scand J Immunol; 2020 Mar; 91(3):e12850. PubMed ID: 31733115
[TBL] [Abstract][Full Text] [Related]
15. Activities of stromal and immune cells in HPV-related cancers.
Barros MR; de Melo CML; Barros MLCMGR; de Cássia Pereira de Lima R; de Freitas AC; Venuti A
J Exp Clin Cancer Res; 2018 Jul; 37(1):137. PubMed ID: 29976244
[TBL] [Abstract][Full Text] [Related]
16. High-risk HPV E5-induced cell fusion: a critical initiating event in the early stage of HPV-associated cervical cancer.
Gao P; Zheng J
Virol J; 2010 Sep; 7():238. PubMed ID: 20846406
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of women diagnosed with carcinoma who tested positive for cervical and anal high-risk human papillomavirus DNA and E6 RNA.
Veo CA; Saad SS; Fregnani JH; Scapulatempo-Neto C; Tsunoda AT; Resende JC; Lorenzi AT; Mafra A; Cinti C; Cotrim ID; Rosa LA; de Oliveira CM; Martins TR; Centrone C; Levi JE; Longatto-Filho A
Tumour Biol; 2015 Jul; 36(7):5399-405. PubMed ID: 25677903
[TBL] [Abstract][Full Text] [Related]
18. Immune evasion in human papillomavirus-associated cervical cancer.
Tindle RW
Nat Rev Cancer; 2002 Jan; 2(1):59-65. PubMed ID: 11902586
[TBL] [Abstract][Full Text] [Related]
19. Signaling pathways in HPV-associated cancers and therapeutic implications.
Chen J
Rev Med Virol; 2015 Mar; 25 Suppl 1():24-53. PubMed ID: 25752815
[TBL] [Abstract][Full Text] [Related]
20. Virus/Host Cell Crosstalk in Hypoxic HPV-Positive Cancer Cells.
Hoppe-Seyler K; Mändl J; Adrian S; Kuhn BJ; Hoppe-Seyler F
Viruses; 2017 Jul; 9(7):. PubMed ID: 28678198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
